Literature DB >> 11962352

Ineffectiveness of the current strategy to prevent hepatitis A in travelers.

Gaston De Serres1, Bernard Duval, Ramak Shadmani, Nicole Boulianne, Gina Pohani, Monika Naus, Monique Douville Fradet, Louis Rochette, Brian J Ward, Kevin C Kain.   

Abstract

BACKGROUND: Each year, a large number of Canadians travel to regions of the world where hepatitis A remains endemic. Many of these travelers are not immune and the current preventive strategy relies wholly on self-referral to a travel clinic. All of the costs associated with such a visit are assumed by the traveler. We estimated the effectiveness of this strategy.
METHODS: This case-control study included 108 travel-related hepatitis A cases with onset of disease between 1997 and 1999 and 620 controls who traveled during the same period.
RESULTS: Hepatitis A was strongly associated with high-risk travel (Odds Ratio = 7.2, 95% Confidence Interval 1.76-29.4), but only 7% of cases were found in this category. The risk of hepatitis A was 5 times lower in travelers who visited a travel clinic than in those who did not (80% efficacy). However, only 14% of the controls visited a travel clinic. As a result, the effectiveness of the current strategy is estimated to be 11% (80% of 14%).
CONCLUSIONS: Hepatitis A in travelers can be prevented effectively by attendance at a travel clinic. Unfortunately, most travelers do not visit such clinics prior to departure. Even if all high-risk travelers were to visit a travel clinic and receive vaccination, this would have negligible impact on the number of travel-related hepatitis A cases (approximately 7% reduction). The current strategy for the prevention of hepatitis A in travelers is ineffective and should be reexamined.

Entities:  

Mesh:

Year:  2002        PMID: 11962352     DOI: 10.1111/j.1708-8305.2002.tb00872.x

Source DB:  PubMed          Journal:  J Travel Med        ISSN: 1195-1982            Impact factor:   8.490


  10 in total

1.  Participant-collected, mail-delivered oral fluid specimens can replace traditional serosurveys: a demonstration-of-feasibility survey of hepatitis A virus-specific antibodies in adults.

Authors:  Jan J Ochnio; David W Scheifele; Stephen A Marion; Mark Bigham; David M Patrick; Margaret Ho; Michelle Mozel
Journal:  Can J Public Health       Date:  2007 Jan-Feb

2.  STATEMENT ON PEDIATRIC TRAVELLERS: Committee to Advise on Tropical Medicine and Travel.

Authors:  S Kuhn; C Hui
Journal:  Can Commun Dis Rep       Date:  2010-06-10

3.  The prevalence of hepatitis A in children in British Columbia.

Authors:  Jan J Ochnio; David W Scheifele; Murray Fyfe; Mark Bigham; David Bowering; Paul Martiquet; Margaret Ho; Douglas N Talling
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-05       Impact factor: 2.471

4.  Hepatitis A vaccination coverage among adults 18-49 years traveling to a country of high or intermediate endemicity, United States.

Authors:  Peng-Jun Lu; Kathy K Byrd; Trudy V Murphy
Journal:  Vaccine       Date:  2013-03-21       Impact factor: 3.641

5.  Hepatitis B vaccination coverage among adults aged ≥ 18 years traveling to a country of high or intermediate endemicity, United States, 2015.

Authors:  Peng-Jun Lu; Alissa C O'Halloran; Walter W Williams; Noele P Nelson
Journal:  Vaccine       Date:  2018-03-28       Impact factor: 3.641

6.  Surveillance of Vaccination Coverage Among Adult Populations -United States, 2018.

Authors:  Peng-Jun Lu; Mei-Chuan Hung; Anup Srivastav; Lisa A Grohskopf; Miwako Kobayashi; Aaron M Harris; Kathleen L Dooling; Lauri E Markowitz; Alfonso Rodriguez-Lainz; Walter W Williams
Journal:  MMWR Surveill Summ       Date:  2021-05-14

Review 7.  A review of interventions triggered by hepatitis A infected food-handlers in Canada.

Authors:  Andrea C Tricco; Ba' Pham; Bernard Duval; Gaston De Serres; Vladimir Gilca; Linda Vrbova; Andrea Anonychuk; Murray Krahn; David Moher
Journal:  BMC Health Serv Res       Date:  2006-12-08       Impact factor: 2.655

8.  Cohort effects in dynamic models and their impact on vaccination programmes: an example from hepatitis A.

Authors:  Arni S R Srinivasa Rao; Maggie H Chen; Ba' Z Pham; Andrea C Tricco; Vladimir Gilca; Bernard Duval; Murray D Krahn; Chris T Bauch
Journal:  BMC Infect Dis       Date:  2006-12-05       Impact factor: 3.090

9.  Trends of hepatitis A hospitalization and risk factors in Quebec, Canada, between 1990 and 2003.

Authors:  Magalie Canuel; Gaston De Serres; Bernard Duval; Rodica Gilca; Philippe De Wals; Vladimir Gilca
Journal:  BMC Infect Dis       Date:  2007-04-18       Impact factor: 3.090

10.  The United States and Canada as a coupled epidemiological system: an example from hepatitis A.

Authors:  Raluca Amariei; Allan R Willms; Chris T Bauch
Journal:  BMC Infect Dis       Date:  2008-02-28       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.